Topical bacitracin ointment may be an appropriate, well-tolerated option for treatment of superficial external ocular bacterial infections.
New York-As the recently released report from the International Workshop on Meibomian Gland Dysfunction (MGD) together with evidence of rising rates of endophthalmitis postcataract surgery are focusing attention on evaluation and management of lid disease, ophthalmologists should not forget that topical bacitracin ointment may be an appropriate, well-tolerated option for treatment of superficial external ocular bacterial infections, said Penny A. Asbell, MD.
This information underscores the importance of carefully evaluating the lids in patients complaining about dry eye-related symptoms and of identifying and treating existing lid margin disease prior to cataract surgery, she said.
Dr. Asbell will be undertaking a clinical trial to investigate the efficacy and safety of topical bacitracin ophthalmic ointment (Fera Pharmaceuticals) in the treatment of lid disease.
"This study aims to take a modern look at the role of bacitracin in the treatment of lid disease and will evaluate its microbiological activity in an era of growing concern about bacterial resistance," she concluded.
Penny A. Asbell, MD
The investigator-initiated study is partially funded by Fera Pharmaceuticals and will use the topical bacitracin ointment marketed by that company. Dr. Asbell has no other relevant financial interests to disclose.